Jade Biosciences (JBIO) vs MoonLake Immunotherapeutics (MLTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Jade Biosciences (JBIO) has outperformed MoonLake Immunotherapeutics (MLTX) over the past year, gaining 52.3% versus a gain of 16.1%. Over five years, MLTX leads with a +8.6% price change compared with -97.2% for JBIO. Jade Biosciences is the larger company by market cap ($872.9 million vs $866.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | JBIO | MLTX |
|---|---|---|
| Share price | $13.73 | $10.18 |
| Market cap | $872.87M | $865.96M |
| 1-day change | -0.33% | -5.52% |
| YTD return | -10.76% | -18.29% |
| 1-year return | +52.32% | +16.06% |
| 5-year return | -97.22% | +8.57% |
| EPS (TTM) | $-1.92 | $-3.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28.00 | $23.29 |
| 52-week low | $8.36 | $8.80 |
| Distance from 52-week high | -50.98% | -56.31% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +265.25% | +180.49% |
| Average volume | 888.66K | 1.44M |
| Shares outstanding | 63.60M | 85.11M |
| Employees | 55 | 130 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- JBIO has outperformed MLTX by 36.3 percentage points over the past year.
About Jade Biosciences
JBIO stock →Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About MoonLake Immunotherapeutics
MLTX stock →MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 130 employees
JBIO vs MLTX FAQ
Which is bigger, Jade Biosciences or MoonLake Immunotherapeutics?
Jade Biosciences (JBIO) is larger, with a market capitalization of $872.87M compared with $865.96M for MoonLake Immunotherapeutics (MLTX).
Which stock has performed better over the past year, JBIO or MLTX?
JBIO returned +52.32% over the past 12 months, compared with +16.06% for MLTX (price return, excluding dividends). Past performance does not predict future results.
Are Jade Biosciences and MoonLake Immunotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.